Shanghai Pharmaceuticals: Dihydroxypropyltheophylline Injection Approved for Production

2026-03-27 11:22:33

On March 26, People’s Financial News reported that Shanghai Pharmaceuticals (601607) announced on March 26 that its subsidiary Shanghai Hefeng Pharmaceutical Co., Ltd. has received the “Drug Registration Certificate” issued by the National Medical Products Administration for its Dihydroxypropyl Theophylline Injection, which has been approved for production. Dihydroxypropyl Theophylline Injection is suitable for relieving symptoms of asthma, asthmatic bronchitis, and obstructive emphysema. It can also be used for wheezing caused by cardiogenic pulmonary edema.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes